Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study aims to provide a basis for further clinical development of YK012.
Phase:
PHASE1
Details
Lead Sponsor:
Excyte Biopharma Ltd
Treatments:
Injections